Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT01999738. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 1A/B, multicenter, open-label, non-randomized, dose-escalation oncology study to evaluate the administration of EC1456 in advanced solid tumors. In part A, EC1456 will be dose escalated on 4 concurrently enrolling schedules. FR-positive expression on a 99mTc-etarfolatide scan is not required for inclusion in Part A. Part B of the study will confirm the maximum tolerated dose (MTD) and the recommended Phase 2 (RP2) dose of EC1456, and evaluate the efficacy of EC1456 in NSCLC all subtype patient populations with FR-positive cancer in up to three schedules (i.e., twice weekly, once weekly, and four times weekly). FR-positive expression on a 99mTc-etarfolatide scan is required for inclusion in Part B. Minimum length of patient participation is anticipated to be 10 weeks (two 3-week cycles followed by a 30 day follow-up period).
Study identification
- NCT ID
- NCT01999738
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 93 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2013
- Primary completion
- Dec 30, 2017
- Completion
- Apr 25, 2018
- Last update posted
- Feb 6, 2019
2013 – 2018
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| Honor Health | Scottsdale | Arizona | 85258 | — |
| University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| City of Hope | Duarte | California | 91010 | — |
| Northwestern University Robert H. Lurie Comprehensive Cancer Center | Chicago | Illinois | 60611 | — |
| IU Health Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202 | — |
| Horizon BioAdvance | Lafayette | Indiana | 47905 | — |
| University of Maryland-Greenebaum Cancer Center | Baltimore | Maryland | 21201-1595 | — |
| Henry Ford Hospital - Josephine Ford Cancer Center | Detroit | Michigan | 48202 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14203 | — |
| Weill Cornell Medical College | New York | New York | 10021 | — |
| University Hospitals Case Medical Center - Seidman Cancer Center | Cleveland | Ohio | 44106 | — |
| Westchase Clinical Associates | Houston | Texas | 77042 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77230 | — |
| University of Vermont Cancer Center | Burlington | Vermont | 05401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01999738, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2019 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01999738 live on ClinicalTrials.gov.